IRIS - Res&Arch Institutional Research Information System - Research & Archive

METRO, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.923
NA - Nord America 2.284
EU - Europa 1.617
SA - Sud America 1.090
AF - Africa 81
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 8.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.174
SG - Singapore 1.124
BR - Brasile 871
VN - Vietnam 497
CN - Cina 468
IT - Italia 364
HK - Hong Kong 347
IE - Irlanda 296
KR - Corea 259
DE - Germania 193
RU - Federazione Russa 176
FI - Finlandia 114
SE - Svezia 97
AR - Argentina 90
GB - Regno Unito 65
FR - Francia 63
RO - Romania 57
IN - India 54
MX - Messico 50
EC - Ecuador 48
AT - Austria 45
CA - Canada 42
ID - Indonesia 39
ZA - Sudafrica 32
PL - Polonia 29
UA - Ucraina 29
BD - Bangladesh 28
JP - Giappone 24
NL - Olanda 23
CO - Colombia 20
ES - Italia 20
PY - Paraguay 20
MA - Marocco 18
IQ - Iraq 15
CL - Cile 13
TR - Turchia 13
PE - Perù 10
DZ - Algeria 9
PK - Pakistan 9
CH - Svizzera 8
EG - Egitto 8
LT - Lituania 8
VE - Venezuela 8
CZ - Repubblica Ceca 7
UY - Uruguay 7
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
TN - Tunisia 5
BY - Bielorussia 4
JO - Giordania 4
SA - Arabia Saudita 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HN - Honduras 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
NI - Nicaragua 3
OM - Oman 3
PH - Filippine 3
AL - Albania 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
EU - Europa 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
MK - Macedonia 2
NP - Nepal 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BS - Bahamas 1
BW - Botswana 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MN - Mongolia 1
NG - Nigeria 1
PS - Palestinian Territory 1
PT - Portogallo 1
PW - Palau 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 8.001
Salva come PNG Salva come JPEG
Città #
Singapore 711
Hong Kong 346
Chandler 331
Dublin 295
Seoul 259
Ho Chi Minh City 169
Perugia 167
Ashburn 166
Boardman 124
Piscataway 121
San Mateo 103
Munich 92
Santa Clara 90
Beijing 89
São Paulo 83
Hanoi 78
Altamura 72
New York 68
Los Angeles 63
Lawrence 58
Medford 58
Princeton 58
Bucharest 57
Dong Ket 57
Hefei 48
Moscow 46
Turku 44
Helsinki 40
Wilmington 40
Andover 30
Rio de Janeiro 28
Redmond 27
Dallas 26
Nuremberg 25
Mexico City 24
Tokyo 23
Brasília 22
Brooklyn 22
Da Nang 22
Warsaw 22
Frankfurt am Main 20
Stockholm 20
Guayaquil 18
Haiphong 18
Johannesburg 18
The Dalles 18
Denver 17
Falkenstein 16
Guarulhos 16
Montreal 16
Poplar 16
San Paolo di Civitate 16
Saint Petersburg 15
Belo Horizonte 14
Biên Hòa 14
Curitiba 14
Orem 14
Atlanta 13
Boston 13
Vienna 13
Buenos Aires 12
Chennai 12
Guangzhou 12
Santo André 12
London 11
Thái Bình 11
Bắc Ninh 10
Manchester 10
Ann Arbor 9
Arezzo 9
Chicago 9
Des Moines 9
Houston 9
Hải Dương 9
Norwalk 9
Quito 9
Amsterdam 8
Ankara 8
Boydton 8
Bắc Giang 8
Rome 8
Salvador 8
San Francisco 8
Seattle 8
Bologna 7
Campinas 7
Mumbai 7
Phủ Lý 7
Ponta Grossa 7
Querétaro 7
Shanghai 7
Asunción 6
Cairo 6
Can Tho 6
Cape Town 6
Caxias do Sul 6
Columbus 6
Franca 6
Hortolândia 6
Lima 6
Totale 4.852
Salva come PNG Salva come JPEG
Nome #
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications 178
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 109
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma 108
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 103
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 103
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 98
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 94
Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. 92
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 91
Non-coding RNAs in lung cancer 90
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 88
Future options for ALK-positive non-small cell lung cancer 84
Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma 84
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 83
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 82
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 81
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 81
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 81
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 79
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles 79
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 79
Sacrum colon-rectal cancer metastasis: Microwave ablation for palliative pain treatment 78
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 78
Inflammatory markers as prognostic factors of survival in patients affected by hepatocellular carcinoma undergoing transarterial chemoembolization 77
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 76
Osimertinib 76
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 75
How might treatment of ALK-positive non-small cell lung cancer change in the near future? 75
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 75
Ercc1 Mrna Expression and Kras Mutation Status In Egfr Wild Type (wt) Advanced Non-small Cell Lung Cancer (nsclc) Patients 74
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 74
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 72
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 72
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 72
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 71
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 68
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 67
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 66
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 66
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 65
Tumour infiltrating lymphocytes (TILs) and PD-L1 expression in malignant pleural mesothelioma. 64
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 63
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 61
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 61
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 60
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 60
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 60
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 59
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care 58
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 58
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 58
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 55
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study 55
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.] 55
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 54
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 54
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 53
Emerging drugs for small cell lung cancer - an update 53
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 53
Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas 52
Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile? 51
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 51
MYC and human telomerase (TERC) gene copy number gain in resected non-small cell lung cancer (NSCLC) 50
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 50
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 49
Abstract 5134: Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC 49
Advances on EGFR mutation for lung cancer 49
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 49
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 47
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 46
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis 46
Clinical experience with gefitinib: an update 46
Prognostic Role of Expression Levels of Fabp3, H19, Tfpi2, Akr1b10 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients 46
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 45
Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) 44
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors 44
2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC 44
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 43
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies 43
Prognostic role of expression levels of FABP3 and AKR1B10 genes in adenocarcinoma stage I patients. 43
Perspectives on salvage therapy for non-small-cell lung cancer 42
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC 42
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer 42
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition) 41
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 41
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 40
Early stage resectable non-small cell lung cancer: Is neoadjuvant immunotherapy the right way forward? 40
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 40
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 40
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer 40
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. 40
Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance 39
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer 39
Non-small-cell lung cancer: how to manage RET-positive disease 39
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 38
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 38
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 37
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib 37
P1.22-19 Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions 36
Non-small-cell lung cancer: how to manage EGFR-mutated disease 36
Totale 6.212
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.422
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.422
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021125 0 0 0 0 0 16 1 9 17 12 10 60
2021/2022498 9 80 3 17 6 6 1 146 30 49 65 86
2022/20231.023 59 214 23 82 95 84 0 38 386 2 30 10
2023/2024459 23 43 30 9 2 3 107 11 26 13 93 99
2024/20251.688 24 96 66 53 139 75 44 125 179 55 579 253
2025/20264.059 399 735 617 1.385 668 255 0 0 0 0 0 0
Totale 8.311